Combined treatment using inhibitors that target cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) together with PD-1 has achieved significant clinical success in treating various cancers, especially melanoma, and resulted in higher survival rates of patients [89]. This evidence concerns the gene PDCD1 and cancer.